The PCR test system demonstrated clinical accuracy in detecting SARS-CoV-2 RNA within 25 minutes, making it an ideal screening tool for international airports….
Xphyto
Xphyto describes itself as “a bioscience accelerator” “targeting growth through commercialization of its product pipeline”….
In lieu of the American markets not opening today courtesy of the civic holiday, Xphyto Therapeutics (XPHY.C) has elected to provide a glimpse into their business strategy and milestones…
On Thursday, December 17th, 2020 the Virtual Life Sciences Investor Forum (VLSIF) presents a six biotech companies….
Today’s federal election results could change the regulatory landscape in Oregon and Washington DC, as the residents of those states will vote to decide if psilocybin should be decriminalised….
Xphyto Therapeutics (XPHY.C) diagnostic partner, 3a-Diagnostics GmbH, is getting onboard with the latest rush to develop a COVID-19 diagnostic kit, using reverse transcription polymerase chain reaction (RT-PCR) technology, which…
Increased product efficacy and patient convenience is anticipated through faster onset of drug action, more predictable therapeutic activity and ease of use….
Xphyto and 3a are developing rapid screening tests for COVID-19 and other high-risk pandemic threats, including H1N1 (swine flu) and H5N1 (avian flu), with a specific focus on early…
Xphyto’s test may be ideal to catch the super-spreaders – the infectious carriers blithely attending drumming circles because they feel healthy….
“Visual confirmation of test results (probe activation) was observed in five to seven minutes,” states Xphyto….